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Atherogenic index of plasma 
and coronary artery calcification 
progression beyond traditional 
risk factors according to baseline 
coronary artery calcium score
Ki‑Bum Won1,2, Donghee Han2,3, Ji Hyun Lee4, Su‑Yeon Choi5, Eun Ju Chun6, Sung Hak Park7, 
Hae‑Won Han8, Jidong Sung9, Hae Ok Jung10 & Hyuk‑Jae Chang2*
This study aimed to evaluate the association between the atherogenic index of plasma (AIP), which 
has been suggested as a novel marker for atherosclerosis, and coronary artery calcification (CAC) 
progression according to the baseline coronary artery calcium score (CACS). We included 12,326 
asymptomatic Korean adults who underwent at least two CAC evaluations from December 2012 to 
August 2016. Participants were stratified into four groups according to AIP quartiles, which were 
determined by the log of (triglyceride/high‑density lipoprotein cholesterol). Baseline CACSs were 
divided into three groups: 0, 1 − 100, and > 100. CAC progression was defined as a difference ≥ 2.5 
between the square roots (√) of the baseline and follow‑up CACSs (Δ√transformed CACS). Annualized 
Δ√transformed CACS was defined as Δ√transformed CACS divided by the inter‑scan period. During a 
mean 3.3‑year follow‑up period, the overall incidence of CAC progression was 30.6%. The incidences 
of CAC progression and annualized Δ√transformed CACS were markedly elevated with increasing 
AIP quartile in participants with baseline CACSs of 0 and 1 − 100, but not in those with a baseline 
CACS > 100. The AIP level was associated with the annualized Δ√transformed CACS in participants 
with baseline CACSs of 0 (β = 0.016; P < 0.001) and 1 − 100 (β = 0.035; P < 0.001), but not in those with 
baseline CACS > 100 (β = 0.032; P = 0.385). After adjusting for traditional risk factors, the AIP was 
significantly associated with CAC progression in those with baseline CACS ≤ 100. The AIP has value for 
predicting CAC progression in asymptomatic adults without heavy baseline CAC.
Coronary artery calcification (CAC) is associated with atherosclerotic burden and adverse cardiovascular (CV) 
clinical  outcomes1‒3. Furthermore, CAC progression is a powerful predictor of mortality beyond traditional 
CV risk  factors4. Recently, the Heinz Nixdorf Recall (HNR) study suggested that CAC progression may only 
offer additional prognostic benefit in the asymptomatic adult population, and that what counts is the baseline 
coronary artery calcium score (CACS) and risk factor  assessment5. In particular, additional CAC evaluation was 
not recommended in cases of heavy baseline CAC, although a high CV risk was present in the HNR  study5. This 
result suggests that early detection of the presence and progression of subclinical atherosclerosis is important in 
conditions with low to intermediate CV risk burden.
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The atherogenic lipoprotein profile of plasma is a substantial risk factor for atherosclerosis. The atherogenic 
index of plasma (AIP) has been considered a marker of plasma atherogenicity based on its strong and positive 
association with lipoprotein particle size, cholesterol esterification rates, and remnant  lipoproteinemia6–8. Nota-
bly, evidence suggests that the AIP may be more closely related to CV risk than are other atherogenic indices or 
individual lipoprotein cholesterol concentrations  alone9–11. However, there is a paucity of data on the association 
between the AIP and CAC progression according to the baseline CACS. Thus, the present study aimed to evaluate 
the association between the AIP and CAC progression, focusing on the baseline CACS.
Methods
Study population and design. Data from the Korea Initiatives on Coronary Artery Calcification (KOICA) 
registry were analyzed in this study. The KOICA registry is a retrospective, observational, and multicenter reg-
istry of self-referred asymptomatic adults who underwent a general health examination at six healthcare centers 
in South  Korea12,13. Briefly, the present study included 12,326 participants who underwent at least two CAC scan 
examinations, with available data on the AIP and diabetic status, from December 2012 to August 2016. All data 
were obtained during visits to each healthcare center. Self-reported medical questionnaires were used to obtain 
information on the participant’s medical history. Blood pressure of the right arm was measured using an auto-
matic manometer, after resting for at least 5 min. Weight and height were measured with the participants wear-
ing light clothing without shoes. The body mass index (BMI) was calculated as the weight in kilograms divided 
by the square of the height in meters. All blood samples were obtained after at least 8 h of fasting and analyzed 
for total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), creatinine, glucose, and glycated hemoglobin A1C (HbA1C) levels. Hypertension was defined as 
systolic blood pressure (BP) ≥ 140 mmHg or diastolic BP ≥ 90 mmHg, a previous diagnosis of hypertension, or 
use of anti-hypertensive medication. Diabetes was defined as either a fasting glucose level ≥ 126 mg/dL, HbA1C 
level ≥ 6.5%, a referral diagnosis of diabetes, or use of anti-diabetic treatment. Hyperlipidemia was defined as a 
total cholesterol level ≥ 240 mg/dL or anti-hyperlipidemic treatment. Obesity was defined as BMI ≥ 25.0 kg/m2 
using cut-offs for the Asian population. Current smoking history was considered present if participants cur-
rently smoked or smoked until 1 month before the study. Hypertension, diabetes, hyperlipidemia, obesity, and 
current smoking status were considered as traditional risk factors. The AIP was defined as the base 10 logarithm 
of the ratio of the concentration of triglycerides to HDL-C6. All participants were categorized into four-groups 
based on AIP quartiles.
CACS was measured using the scoring system described by Agatston et al.14. CAC progression was defined 
using the SQRT method; specifically, as a difference ≥ 2.5 between the square roots (√) of the baseline and follow-
up CACSs (Δ√transformed CACS), with consideration of the inter-scan  variability4,15. Annualized Δ√transformed 
CACS was defined as Δ√transformed CACS divided by the inter-scan period. All computed tomography (CT) 
scans used to assess CAC were obtained from a > 16-slice multi-detector CT scanner (Philips Brilliance 256 iCT 
[Philips Healthcare, Cleveland, OH], Philips Brilliance 40-channel multi-detector CT [Philips Healthcare], GE 
64-slice Lightspeed [GE Healthcare, Milwaukee, WI], and Siemens 16-slice Sensation [Siemens, Forchheim, Ger-
many]). Standard prospective or retrospective methods were used in all centers. All methods were performed in 
accordance with the relevant guidelines and regulations. The appropriate institutional review board committees 
of Severance Cardiovascular Hospital approved the protocol of the present study.
Statistical analysis. Continuous variables are expressed as the mean ± standard deviation. Categorical 
variables are expressed as absolute values and percentage. The one-way analysis of variance was used to analyze 
continuous variables. The χ2 or Fisher’s exact test was used to analyze categorical variables, as appropriate. 
Univariate linear regression analysis was used to assess the association of clinical variables with the annualized 
Δ√transformed CACS in each categorical CACS group. Multiple logistic regression models were used to identify 
the independent predictive value of the AIP for CAC progression beyond that for traditional risk factors accord-
ing to the baseline CACS status, using the forced entry method. Relative risk was estimated by a log-binomial 
regression analysis for generalized linear models. All statistical analyses were performed using the Statistical 
Package for the Social Sciences version 19 (SPSS, Chicago, IL) and SAS version 9.1.3 (SAS Institute Inc., Cary, 
NC). A P value < 0.05 was considered significant in all analyses.
Ethics approval and consent to participate. The protocol of the present study was approved by the 
institutional review board of each institution, and written informed consent was obtained from each participant.
Results
Baseline characteristics. Clinical characteristics of the 12,326 participants (10,382 men [84.2%]) are pre-
sented in Table 1. The mean age of the participants was 51.7 ± 8.5 years. The traditional risk factors of hyperten-
sion, diabetes, hyperlipidemia, and current smoking were observed in 33.5%, 13.8%, 28.0%, and 28.5% of par-
ticipants, respectively. The mean levels of the AIP quartile-stratified groups of I (lowest), II, III, and IV (highest) 
were 0.007 ± 0.129, 0.274 ± 0.057, 0.469 ± 0.058, and 0.759 ± 0.154, respectively. Systolic and diastolic BP, BMI, 
the levels of total cholesterol, triglyceride, glucose, and HbA1C, and the prevalence of male sex, hypertension, 
diabetes, hyperlipidemia, and current smoking were significantly increased with increasing AIP quartile. In con-
trast, the mean level of HDL-C was significantly decreased with increasing AIP quartile. Clinical characteristics 
according to CAC progression are described in Supplementary Table 1.
Baseline and changes in CAC . The overall prevalence of baseline CACSs of 0, 1–100, and > 100 were 
56.2%, 33.2%, and 10.6%, respectively. A significant difference in the proportion of categorical CACS among the 
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21324  | https://doi.org/10.1038/s41598-020-78350-x
www.nature.com/scientificreports/
three groups was observed (Supplementary Fig. 1). During the follow-up period of 3.3 ± 1.8 years, CAC progres-
sion was observed in 30.6% of participants. The incidence of CAC progression (group I: 23.3% versus [vs.] group 
II: 29.6% vs. group III: 33.2% vs. group IV: 36.3%; P < 0.001), Δ√transformed CACS (group I: 1.69 ± 3.97 vs. 
group II: 2.33 ± 4.79 vs. group III: 2.69 ± 4.95 vs. group IV: 2.96 ± 5.06; P < 0.001), and annualized Δ√transformed 
CACS (group I: 0.49 ± 1.48 vs. group II: 0.66 ± 1.64 vs. group III: 0.74 ± 2.18 vs. group IV: 0.81 ± 1.65; P < 0.001) 
were elevated with increasing AIP quartile (Fig. 1).
Table 1.  Clinical characteristics of the study cohort. Values are presented as the mean ± standard deviation 
or number (%). AIP atherogenic index of plasma, BMI body mass index, BP blood pressure, HbA1C glycated 
hemoglobin A1C, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol.
Total (n = 12,326)
Quartiles of AIP
P
I (lowest) (n = 3103) 
0.620 − 0.170 II (n = 3064) 0.171 − 0.369 III (n = 3085) 0.370 − 0.575
IV (highest) (n = 3074) 
0.576 − 1.738
Age, years 51.7 ± 8.5 51.6 ± 9.0 52.1 ± 8.6 52.2 ± 8.4 50.9 ± 7.9  < 0.001
Male, n (%) 10,382 (84.2) 2,134 (68.8) 2,573 (84.0) 2,793 (90.5) 2,882 (93.8)  < 0.001
Systolic BP, mmHg 119.6 ± 15.0 117.5 ± 15.1 119.5 ± 15.1 120.1 ± 15.0 121.1 ± 14.6  < 0.001
Diastolic BP, mmHg 75.0 ± 10.5 72.9 ± 10.7 75.0 ± 10.5 75.5 ± 10.4 76.8 ± 10.2  < 0.001
BMI, kg/m2 24.6 ± 2.8 23.3 ± 2.7 24.3 ± 2.6 25.0 ± 2.6 25.7 ± 2.6  < 0.001
Traditional risk factors
Hypertension, n (%) 4,016 (33.6) 806 (27.0) 965 (32.6) 1,095 (36.6) 1,150 (38.3)  < 0.001
Diabetes, n (%) 1,703 (13.8) 300 (9.7) 367 (12.0) 502 (16.3) 534 (17.4)  < 0.001
Hyperlipidemia, n (%) 3,455 (28.0) 587 (18.9) 767 (25.0) 926 (30.0) 1,175 (38.2)  < 0.001
Obesity, n (%) 5,178 (42.2) 760 (24.6) 1,153 (37.8) 1,468 (47.8) 1,797 (58.6)  < 0.001
Current smoking, n (%) 3,229 (28.5) 529 (18.6) 669 (23.9) 891 (31.4) 1,140 (40.1)  < 0.001
Laboratory
Total cholesterol, mg/dL 197.5 ± 34.0 191.9 ± 32.1 195.5 ± 33.6 198.0 ± 34.0 204.6 ± 35.1  < 0.001
Triglyceride, mg/dL 141.7 ± 89.4 69.9 ± 19.9 103.2 ± 21.9 143.1 ± 29.7 250.9 ± 108.1  < 0.001
HDL-C, mg/dL 53.3 ± 16.0 68.3 ± 19.3 54.7 ± 10.9 48.5 ± 9.0 41.8 ± 7.7  < 0.001
LDL-C, mg/dL 122.0 ± 31.7 110.2 ± 30.8 123.8 ± 31.0 128.0 ± 30.5 126.1 ± 31.5  < 0.001
Fasting glucose, mg/dL 97.8 ± 20.3 92.9 ± 16.3 96.6 ± 17.8 99.4 ± 20.7 102.3 ± 24.4  < 0.001
HbA1C, % 5.7 ± 0.7 5.5 ± 0.6 5.6 ± 0.7 5.7 ± 0.8 5.8 ± 0.9  < 0.001
AIP 0.377 ± 0.295 0.007 ± 0.129 0.274 ± 0.057 0.469 ± 0.058 0.759 ± 0.154  < 0.001
Figure 1.  Changes in CAC according to AIP quartile. (a) CAC progression; (b) Δ√transformed CACS and 
annualized Δ√transformed CACS. AIP atherogenic index of plasma, CAC coronary artery calcification, CACS 
coronary artery calcification score.
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AIP and CAC change in each baseline CACS. The incidence of CAC progression was elevated with 
increasing AIP quartile in those with baseline CACSs of 0 (8.8% vs. 11.8% vs. 15.3% vs. 17.1%, P < 0.001) and 
1–100 (49.0% vs. 52.7% vs. 54.1% vs. 56.7%, P = 0.006), but not in those with baseline CACS > 100 (46.4% vs. 
52.0% vs. 54.3% vs. 55.5%, P = 0.131). The annualized Δ√transformed CACS was significantly different among 
AIP quartiles in those with baseline CACSs of 0 (0.14 ± 0.52 vs. 0.18 ± 0.59 vs. 0.24 ± 0.71 vs. 0.27 ± 0.72, P < 0.001) 
and 1–100 (1.10 ± 1.63 vs. 1.31 ± 2.00 vs. 1.40 ± 1.97 vs. 1.36 ± 1.71, P = 0.002), but not in those with baseline 
CACS > 100 (1.11 ± 3.53 vs. 1.23 ± 2.80 vs. 1.09 ± 5.01 vs. 1.52 ± 3.08, P = 0.419) (Fig. 2).
Figure 2.  Changes in CAC according to AIP quartile and baseline CACS. (a) CAC progression; (b) annualized 
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AIP and CAC change according to baseline CACS. The AIP (per 0.1-unit increase) was associated 
with the annualized Δ√transformed CACS in those with baseline CACSs of 0 (β = 0.016; P < 0.001) and 1–100 
(β = 0.035; P < 0.001). However, no significant association between the AIP and annualized Δ√transformed 
CACS was observed in those with baseline CACS > 100 (β = 0.032; P = 0.385) (Table 2). With regards to the asso-
ciation between the AIP and the risk of CAC progression according to the baseline CACS, after adjusting for age, 
sex, hypertension, diabetes, hyperlipidemia, obesity, and current smoking, multiple logistic regression models 
showed that the AIP (per 0.1-unit increase) was significantly associated with an increased risk of CAC progres-
sion in those with baseline CACSs of 0 and 1–100. However, this association between the AIP and the risk of 
CAC progression was not observed in those with baseline CACS > 100 (Table 3).
Discussion
The present study demonstrated that, during the mean 3.3-year follow-up period, the AIP level was significantly 
related to the annualized Δ√transformed CACS in participants with baseline CACS ≤ 100 in 12,326 participants 
from the asymptomatic Korean population. After adjusting for traditional risk factors, the AIP was significantly 
associated with an increased risk of CAC progression in these participants.
Budoff et al. previously reported that CAC progression had additive value in predicting all-cause mortal-
ity, beyond that for the baseline score and CV risk factors, in 4,609 asymptomatic participants who underwent 
repeat screening during a mean 3.1-year  period4. In contrast, the CCLS (Cooper Center Longitudinal Study) trial 
found only a modest association between CAC progression and CV outcomes, although additional prognostic 
information was not provided in comparison with that for the latest single CAC value, during the mean 3.5-year 
 period16. Lehmann et al. recently reported that CAC progression may only add prognostic benefit for participants 
without CV disease, based on the HNR study data (n = 3,281), during a mean 5.1-year follow-up5. This previous 
study emphasized the significance of the most recent CAC value and risk factor assessment. Additional CAC 
Table 2.  Clinical variables and annualized Δ√transformed CACS according to baseline CACS. AIP 
atherogenic index of plasma, BMI body mass index, BP blood pressure, CACS coronary artery calcium score, 
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol.
Variables
CACS 0 CACS 1–100 CACS > 100
β SE P β SE P β SE P
Age, pre-1 year increase 0.012 0.001  < 0.001 0.016 0.004  < 0.001 0.007 0.012 0.584
Male 0.144 0.019  < 0.001 0.546 0.092  < 0.001 0.724 0.372 0.052
Systolic BP, per-1 mmHg increase 0.003 0.001  < 0.001  − 0.001 0.002 0.692  − 0.005 0.007 0.438
Diastolic BP, per-1 mmHg increase 0.004 0.001  < 0.001  − 0.011 0.003 0.001  − 0.008 0.010 0.440
BMI, per-1 kg/m2 0.019 0.003  < 0.001 0.051 0.011  < 0.001 0.058 0.038 0.123
Total cholesterol, per-1 mg/dL increase 0.001 0.001  < 0.001  − 0.002 0.001 0.020 0.001 0.003 0.953
Triglyceride, per-1 mg/dL increase 0.001 0.001  < 0.001 0.001 0.001  < 0.001 0.001 0.001 0.268
HDL-C, per-1 mg/dL increase  − 0.001 0.001 0.053 0.001 0.002 0.583 0.001 0.007 0.940
LDL-C, per-1 mg/dL increase 0.001 0.001  < 0.001 0.001 0.001 0.359 0.001 0.003 0.774
AIP, per-0.1 unit increase 0.016 0.003  < 0.001 0.035 0.010  < 0.001 0.032 0.037 0.385
Fasting glucose, per-1 mg/dL increase 0.004 0.001  < 0.001 0.007 0.001  < 0.001 0.001 0.004 0.941
Current smoking 0.159 0.045  < 0.001 1.028 0.177  < 0.001 2.107 0.514  < 0.001
Table 3.  Impact of the AIP (per 0.1-unit increase) on CAC progression, beyond traditional risk factors, 
according to baseline categorical CACS. Models: 1 = unadjusted; 2 = adjusted for age, sex, and the traditional 
risk factors of hypertension, diabetes, hyperlipidemia, obesity, and current smoking. AIP atherogenic index 
of plasma, BMI body mass index, CAC coronary artery calcification, CACS coronary artery calcium score, CI 
confidence interval, OR odds ratio, RR relative risk.
OR (95% CI) P RR (95% CI) P
CACS 0
Model 1 1.10 (1.08–1.13)  < 0.001 1.09 (1.07–1.11)  < 0.001
Model 2 1.05 (1.02–1.08) 0.001 1.04 (1.02–1.06) 0.001
CACS 1–100
Model 1 1.04 (1.02–1.07)  < 0.001 1.02 (1.01–1.03)  < 0.001
Model 2 1.03 (1.01–1.05) 0.022 1.01 (1.01–1.02) 0.020
CACS > 100
Model 1 1.05 (1.01–1.09) 0.019 1.02 (1.01–1.04) 0.018
Model 2 1.00 (0.96–1.05) 0.940 1.00 (0.98–1.02) 0.928
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examination is not required in cases of heavy CAC at baseline, which implies the presence of a high CV risk. 
Considering that atherosclerosis-related adverse events commonly occur, even in populations with low CV risk 
 burden17–19, these results strongly suggest that early detection of the presence and progression of subclinical 
atherosclerosis is an important issue in clinical practice.
Previous studies revealed that the AIP is significantly related to diverse metabolic disorders, such as fatty liver 
disease, hypertension, and  diabetes20,21. In addition, a number of cross-sectional studies demonstrated that the 
AIP had predictive value for coronary artery disease in various clinical  conditions22–24. However, earlier studies 
did not address the relationship between the AIP and CAC progression, especially in terms of the baseline CACS. 
In the present study, we considered a CACS > 100 as indicating heavy CAC status based on the following facts: 
(1) Nasir et al.25 reported that the frequency of CACS > 100 in the Asian population is significantly lower than 
that in western populations; and (2) the overall proportion of baseline CACS > 100 was 10.6% in our partici-
pants. The presence of CAC at baseline and CAC progression during follow-up were more frequently observed 
with increasing AIP quartile. However, the AIP was associated with the risk of CAC progression, over that for 
traditional CV risk factors, in participants without heavy CAC at baseline. This finding suggests that the AIP is 
a useful marker for the stratification of CV risk, in addition to the baseline CAC status, in conditions with low 
to intermediate CV risk.
Because the present study only evaluated the change in CACS in the asymptomatic adult population, data on 
changes in the regional distribution or pattern of CAC were unavailable. In addition, the effect of medications 
such as statins, which could influence the changes in plaque sub-types, was not  considered26. However, a recent 
CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) sub-
study found that further prognostic benefit was not offered by coronary computed tomographic angiography 
(CCTA) findings when added to traditional risk factors and CACS in 1,226 asymptomatic participants, during 
a mean 5.9 ± 1.2 years of follow-up27. This finding suggests that CCTA may have a limited role in future CV risk 
stratification in the asymptomatic population, until further proven.
We should acknowledge some limitations of the present study. First, this study included participants from the 
KOICA registry who underwent at least two CAC scans with available data on the AIP and diabetic status. Thus, 
a potential selection bias might be present. Second, we only identified the association between the baseline AIP 
level and CAC progression, focusing on the baseline CACS; consecutive changes in AIP during the follow-up 
period were not confirmed. However, the mean change in the AIP between the initial and follow-up CAC scan 
was very small: − 0.02 ± 0.23. Third, the use of medications for hypertension, diabetes, and hyperlipidemia was 
not controlled during the follow-up period because this study had an observational design. Fourth, although we 
evaluated the predictive value of the AIP for CAC progression after adjusting for sex, the predominance of male 
sex in this cohort registry could have impacted the results. Thus, it might be hard to apply the results of present 
study to the female population. Fifth, although this study was performed in an asymptomatic and relatively 
healthy population, there was a paucity of data on environmental risk factors, such as physical activity, exercise, 
and diet, which could influence CAC progression. Sixth, different CT scanners were used among the participat-
ing centers because the KOICA registry was a retrospective, observational, and multicenter registry. However, 
all participants were examined using the identical CT scanner at both the initial and follow-up image acquisi-
tions. Finally, the generalizability of our results may be limited considering that all participants were Korean. 
Despite these limitations, we firstly identified the predictive value of the AIP for CAC progression according to 
the baseline CACS in a large sample of the asymptomatic adult population.
Conclusion
In summary, the present study demonstrates that the AIP is independently associated with CAC progression, 
especially in the absence of heavy CAC at baseline. This result suggests that the AIP has the potential to predict 
early coronary atherosclerotic changes and to stratify CV risk in asymptomatic adults with low to intermediate 
CV risk. Further large-scale prospective studies are necessary to confirm the significance of the AIP in primary 
prevention.
Data availability
The datasets used and analyzed during the current study are available from the corresponding author on reason-
able request.
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